Open AccessHealthcare Facility-Associated Clostridium difficile Infection in Hospitalized Patients Receiving Intravenous Beta-Lactam Antibiotics in the Veterans Affairs Healthcare System (VHA)
Author(s) -
Brigid Wilson,
Federico Pérez,
Elie Saade,
Curtis J. Donskey
Publication year - 2016
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofw172.1615
Subject(s) - medicine , clostridium difficile , veterans affairs , health care , antibiotics , intravenous antibiotics , beta lactam , intensive care medicine , emergency medicine , medical emergency , microbiology and biotechnology , economics , economic growth , biology
Background • Antibiotic exposure in the intestinal tract is the most important risk factor for Clostridium difficile infection (CDI) • Oral administration of beta-lactamase enzymes such as SYN-004 (Synthetic Biologics, Inc) has been effective in eliminating the portion of intravenous beta-lactam antibiotics excreted into the intestinal tract, preserving the microbiota during therapy • We examined patterns of use of beta-lactams and the relative frequency of healthcare facilityassociated (HCFA)-CDI associated with them given alone or combined with other antibiotics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom